Background: A local imbalance between regulatory (Treg) and effector T cells is believed to play a major role in gut-specific inflammation, including
U lcerative colitis (UC) is a chronic destructive, inflammatory disorder of the gastrointestinal tract leading to bloody diarrhea, weight loss, and abdominal pain. In general, therapy is dominated by immunosuppressive drugs, such as corticosteroids, azathioprine, cyclosporine A, and biologicals, such as anti-tumor necrosis factor antibodies and the anti-integrin a4b7 antibody vedolizumab. Unfortunately, these drugs are only effective in subgroups of patients, and in severe and/or therapy refractory cases, surgical removal of the colon is necessary. 1, 2 Regulatory T cells (Treg) play a critical role in maintaining immune homeostasis and limiting autoimmune responses by modulation of both innate and adaptive immunity. 3 Classically defined Treg are characterized by their constitutive expression of CD4, CD25, and FoxP3, 4 and they can suppress CD4 + and CD8 + T-cell-mediated immune responses in vitro and in vivo through various mechanisms, including the secretion of inhibitory cytokines, granzyme-mediated cytotoxicity, CTLA-4 expression, metabolic disruption, and dendritic cell targeting. 5, 6 The possibility of Treg-based immunotherapy for treatment of human gutspecific inflammation is increasingly considered. Specifically, the adoptive transfer of Treg has shown preclinical efficacy in mice because mucosal inflammation was reduced or prevented in various experimental colitis models, [7] [8] [9] [10] and ovalbuminspecific Treg cells have successfully been tested for their therapeutic potential in patients with Crohn's disease. 11 Also, the presence and function of Treg in patients with UC has previously been demonstrated, 12, 13 and it is now believed that a local imbalance between Treg and effector T cells plays a role in UC-specific gut inflammation. 10 Together, these studies highlight the potential of adoptively transferred Treg as a novel treatment modality in UC.
In the past years, various strategies to isolate and expand Treg from peripheral blood have been described. [14] [15] [16] In addition, to date, 8 adoptive Treg transfer clinical studies have been published, 11, [17] [18] [19] [20] [21] [22] [23] and several others are currently ongoing (www.clinicaltrials.gov). In general, implementation of clinical Treg expansion protocols is hampered by the difficulties associated with large-scale production of Treg in compliance with Good Manufacturing Practices (GMP). In particular, Treg function should carefully be controlled in a clinical setting including the unwanted outgrowth of effector T cells, which may contaminate the final Treg product.
The concurrent expansion of effector T cells from the starting CD25 + cell population is circumvented through the use of cord blood-derived CD25 + cells 19 or through the addition of the immunosuppressive drug rapamycin to the culture media. The latter effectively blocks the expansion of effector T cells without affecting Treg proliferation. 24, 25 Importantly, rapamycinexpanded Treg are not contaminated by IL-17-producing (Th17) T cells and have been shown to maintain a stable phenotype on in vivo transfer in mice. 26 In addition, rapamycinexpanded Treg ameliorated established colitis in a severe combined immunodeficient (SCID) mouse model, whereas treatment with rapamycin alone only partially reversed symptoms. 27 The objective of this study was to test if functional Treg cells could be expanded from peripheral blood mononuclear cells (PBMCs) derived from patients with UC and simultaneously to design a GMP-conform protocol for the ex vivo production of large numbers of Treg derived from whole blood from patients with UC to set the stage for a phase I safety study on Treg transfer in patients with moderate to severe UC.
MATERIALS AND METHODS

Cells
With prior patient consent and under approval of the institutional review board, PBMCs were isolated from whole blood samples obtained from patients with UC using density gradient centrifugation. A total of 8 patients with histologically proven UC were recruited within the outpatient clinic of the Department of Medicine 1 (Gastroenterology, Pneumology and Endocrinology). Recruited patients presented with no/mild disease activity, mild disease activity, or moderate/severe disease activity and received current standard of care and therapy. Demographic data on all included patients are provided in Table 1. CD25 + cells were obtained by positive magnetic cell sorting using CD25 + cell isolation beads (Miltenyi Biotec, Bergisch Gladbach, Germany) according to the manufacturer's instructions. The CD25 2 "left-over" cell fraction was viably frozen in human serum albumin supplemented with 20% glucose and 10% dimethyl sulfoxide and stored at 2808C until used.
CD25 + cells were cultured in X-VIVO15 (Lonza, Brainel'Alleud, Belgium) supplemented with 2 mM L-glutamine (Lonza), 20 mg/mL gentamicin (Lonza), 0.1 mg/mL rapamycin (Santa Cruz Biotechnology, Heidelberg, Germany), 500 U/mL IL-2 (Proleukin), and 5% autologous serum (hereafter called cX-VIVO15) at 378C in 5% CO 2 .
Treg Expansion-conform GMP Protocol
For many years, the Department of Dermatology of the FAU Erlangen holds responsibility for a state-of-the-art GMP facility and is GMP certified to produce dendritic cells under GMP conditions for clinical purposes. Based on this experience and to accelerate future clinical translation of the presented findings, an ex vivo Treg expansion protocol including solely GMP-ready or GMP-exchangeable reagents was designed. With some minor modifications, the presented Treg expansion protocol has recently undergone on-site GMP-conform evaluation, and the manufacturing process has now received GMP certification from the Bavarian government.
Ex Vivo CD25 + Cell Expansion CD25 + cells (2.5 · 10 4 ) were incubated with Treg Expander Beads (Miltenyi Biotec, Bergisch Gladbach, Germany) at a 1:4 ratio in a 96-well tissue plate in cX-VIVO15. Half of the culture medium was replaced every 2 to 3 days with fresh cX-VIVO15 and cells were split when confluent. After 21 days, CD25 + cells were harvested, counted and used immediately in subsequent experiments, or frozen at 2808C. until used (Fig. 1 ).
Flow Cytometry
Cell phenotype was determined before and after 21 days of expansion by staining with directly conjugated mouse anti-human antibodies (mAbs) against CD3 (clone SK7), CD8 (clone SK1), CTLA-4 (clone UC10-4F10-11), CD4 (clone SK3), CD25 (clone BC96), CD127 (clone eBioRDR5), FoxP3 (clone PCH101), helios (clone 22F6), glycoprotein A repetitions predominant (GARP) protein (clone G14D9) and latency-associated peptide (LAP, clone FNLAP). Helios is a transcription factor known to directly regulate Treg function. 28 By contrast, LAP forms a complex with latent transforming growth factor-b1, 29 a cytokine known to play an important role in Treg differentiation, whereas GARP is a receptor for transforming growth factor-b on Treg. 30 Overall, these molecules are associated with immunosuppressive function. Corresponding mouse IgGs, rat IgG2a or hamster IgG1, were used as isotype controls. Intracellular staining was performed using an FoxP3/Transcription Staining Buffer Set (eBioscience, San Diego, CA) according to the manufacturer's instructions. Dead cells were excluded by labeling with Life Dead Aqua (Life Technologies) according to the manufacturer's instructions. The number of degranulating Treg cells was determined by staining with CD107a mAb (clone H4A3) as previously described. 31 In brief, cocultures were incubated for 1 hour at 378C in 5% CO 2 in the presence of the CD107a mAb, after which brefeldin A and monensin (both BD Biosciences) were added. After an additional 5 hours, cocultures were subsequently stained for CD3, CD4, CD8, CD25, CD127, and FoxP3.
Cells were acquired using an FACS Canto II (Becton Dickinson), and data were analyzed using FlowJo and BD FACS DIVA software.
Epigenetic Analysis Using Bisulfite Treatment and Methylation-specific Quantitative Polymerase Chain Reaction Genomic cellular DNA was isolated using a high pure PCR template preparation kit (Roche). Next, sodium bisulfite conversion of the purified DNA was performed using the EpiTect Fast DNA Bisulfite Kit (Qiagen) according to the manufacturer's instructions. The following primers and probe enabled us to specifically detect methylated FoxP3 32 :
Primers and probes for the detection of unmethylated FoxP3 were designed accordingly:
Quantitative polymerase chain reaction was performed using the maxima probe qPCR master mix (Thermo Fisher Scientific) and a C1000TM Thermal Cycler (Bio-Rad . Because the male FoxP3 Treg-specific demethylated region is described to be fully demethylated, and the female Treg-specific demethylated region shows hemimethylation, 34 the above-described calculation would underestimate the relative number of hypomethylated Treg in cells derived from human donors. To circumvent an underestimation, the methylation index for female-derived probes was corrected using the following formula: meth. 
Treg-mediated Suppression of Proliferation
Cryopreserved autologous CD25 2 cells were thawed, washed, and labeled with 5 mM carboxyfluorescein succinimidyl ester (CFSE) (Thermo Fischer Scientific, Carlsbad, CA, USA). Cocultures were routinely performed in triplicates in U-bottom 96-well plates. In the majority of experiments, a total of 1 · 10 5 Treg (1:1 ratio), 2 · 10 4 Treg (1:5 ratio), and 1 · 10 4 Treg (1:10 ratio) were added to a total of 1 · 10 5 CD25 2 responder cells. Cocultures were stimulated with anti-CD3-coated and anti-CD28-coated beads (MACS GMP ExpAct Treg Kit, Miltenyi Biotec) at a bead-to-cell ratio of 1:1. Cocultures were harvested after 4 days, stained with CD3, CD4, and CD8 mAb, and proliferation as measured by CFSE dilution was analyzed by flow cytometry. Separate CD4 + and CD8 + responder cell populations were analyzed by gating on CD3 + CD4 + /CFSE + cells and CD3 + CD8 + /CFSE + cells, respectively. The gates to measure proliferation were set to include, at least, 95% of nonproliferated cells in the unstimulated control. In some experiments, CD25 + cells were separated from the CD25 2 responder cells through the addition of a transwell membrane (hereafter called "insert") (Corning, Wiesbaden, Germany).
To determine the separate function of the CD4 + and CD8 + cell subsets in the expanded CD25 + cell population, CD25 + expanded cells were stained with CD3, CD4, and CD8 mAb and subsequently sorted in separate CD4 + and CD8 + cell subsets using an FACSAria II flow cytometer (BD Biosciences). Expanded CD25 + cells and FACS-sorted CD4 + and CD8 + cell subsets were cocultured with CFSE-labeled responder cells as described above under "Treg-mediated Suppression of Proliferation" and assessed for responder cell proliferation in the presence of expanded CD25 + cells.
Isolation of Colon-derived Responder Cells
With prior patient consent and under approval of the institutional review board, biopsies were obtained from the colon of 4 patients with UC and 8 patients with Crohn's disease (CD) undergoing routine colonoscopy in the outpatient clinic of the Department of Medicine 1. Colon-derived cells were isolated as previously described. 35 In brief, biopsies were washed in phosphate-buffered saline to remove feces, placed in Hank's balanced salt solution (HBSS) (without Ca 2+ Mg 2+ ) containing 5 mM EDTA, 5% FCS, and 10 mM HEPES, and incubated at a shaker for 20 minutes at 378C. This step was repeated once. After predigestion, biopsies were washed in HBSS (without Ca 2+ Mg 2+ ) and 10 mM HEPES, transferred into C tubes (Miltenyi), and subsequently incubated in HBSS (with Ca 2+ Mg 2+ ), 10 mM 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid (HEPES), 5% fetal calf serum (FCS), and digestion enzymes (Miltenyi) at a shaker for 30 minutes at 378C. Finally, digested biopsies were dissociated into single cells using a gentleMACS Dissociator (Miltenyi) with the program preset for intestine. After dissociation, cells were resuspended in cold phosphate-buffered saline containing 0.5% FCS and passed through a 40-mm cell strainer, washed in phosphate-buffered saline, and resuspended in culture medium.
Treg-specific Cytokine Production
CD25 + cells were plated in X-VIVO15 supplemented with 5% autologous serum at a final concentration of 1 · 10 6 /mL in a 24-well plate. T-cell receptor (TCR)-mediated stimulation was induced through the addition of anti-CD3 and anti-CD28 expander beads (Miltenyi Biotec) at a cell-to-bead ratio of 1:1. To preserve intracellular cytokines, 5 mg/mL brefeldin A (Sigma) and 1.5 mg/mL monensin (Sigma) were added to the cell culture medium after 60 minutes of stimulation. CD25 + cells were incubated for a total of 6 or 16 hours at 378C in 5% CO 2 . Unstimulated CD25 + cells served as internal controls.
Intracellular staining of IL-2 (clone MQ1-17H12), IL-10 (clone JES3-9D7), IFNg (clone 4S.B3), and IL-17 (clone eBio64-DEC17) was performed using an FoxP3/Transcription Staining Buffer Set as described under Flow Cytometry.
Assessment of TCR Vb Repertoire
TCR Vb repertoire of ex vivo expanded CD25 + cells was determined using the IO Test Beta Mark TCR Vb Repertoire kit (Beckman Coulter, France), which consists of monoclonal antibodies (mAbs) to 24 distinct TCR Vb families (approximately 70% coverage of normal human TCR Vb repertoire). CD25 + cells were stained and analyzed for TCR Vb usage according to the manufacturer's instructions.
Statistical Analysis
Statistical significance as measured by a 2-sided paired Student's t test was calculated using Excel v2010, based on the number of experiments as indicated in the figure legends. Differences were considered to be significant at a P value less than 0.05.
ETHICAL CONSIDERATIONS
This study was approved by the local Institutional Review Board (IRB) of the Friedrich-Alexander Universität ErlangenNürnberg under IRB number 151_12 B (Department of Dermatology) and IRB number 4439 (Department of Medicine 1). In agreement with IRB approval, oral and written consent was obtained from all UC and CD patients who donated blood or tissue for this study.
RESULTS
Polyclonal, Hypomethylated, and IL-17-negative CD25 + Bulk Cells Are Efficiently Expanded from Patients with UC in the Presence of GMP-conform Reagents To achieve ex vivo expansion of Treg cells from patients with UC, CD25 + cells were enriched from PBMCs using CD25 + isolation beads. This 1-step enrichment approach was chosen because a limited amount of blood (40 mL) was permitted by the IRB to draw per patient per visit for experimental purposes. As a result, insufficient numbers of PBMCs were available to perform a multistep CD25 + enrichment approach. Under our experimental conditions, the enriched CD25 + cell population consisted of CD4 + CD25 + and CD8 + CD25 + T cells and is hereafter called "bulk CD25 + cells." CD25 + bulk cells were subsequently cocultured at a 1 to 4 ratio with anti-CD3/anti-CD28 beads in the presence of IL-2 and rapamycin for 21 days as shown in Figure 1 . After 21 days of culture, CD25 + bulk cells derived from patients with UC expanded greater than 2 orders of magnitude (mean 262 fold, median 138 fold, range 22-778 fold, n ¼ 9), and expansion efficiency was not affected by sex, disease severity, and drug-induced immunosuppression (Table 1) . Further characterization revealed that expanded CD25 + cells remained hypomethylated at intron 1 of the FoxP3 locus ( Fig. 2A, P ¼ 0.5471) and expressed 89.6% CTLA-4 (range 75.9%-99.8%, n ¼ 7), 45.9% helios (range 28.5%-66.4%, n ¼ 7), 9.6% GARP (range 3.8%-12.8%, n ¼ 3), and 19.9% LAP (range 10.8%-24.6%, n ¼ 3) (Fig. 2B-C) , which are molecules associated with immunosuppression of T cells. 28, 36 Moreover, after 6 and 16 hours, UCexpanded Treg produced low levels of the proinflammatory cytokines IL-2 (mean 14.8%, range 1.2%-38.4% after 6 hours and mean 12.3%, range 0.6%-23.9% after 16 hours), IFNg (mean 21.2%, range 2.3%-38.0% after 6 hours and mean 8.9%, range 2.8%-14.0% after 16 hours) and IL-17 (mean 4.3%, range 3.0%-6.3% after 6 hours and mean 1.7%, range 0.5%-3.2% after 16 hours) and the suppressive cytokine IL-10 (mean 5.9%, range 0.6%-13.1% after 6 hours and mean 3.2%, range 0.3%-8.1% after 16 hours) on TCR stimulation (Fig. 2D-F) . No statistical differences were found between the 2 measured time points (IL-2 P ¼ 0.8396, IFNg P ¼ 0.5019, IL-17 P ¼ 0.1535, and IL-10 P ¼ 0.7371). These data suggest that most UCexpanded CD25 + bulk cells do not represent effector T cells, IL-17-secreting helper T cells, or IL-10-producing T-cell clones.
Moreover, CFSE dilution assays confirmed the suppressive nature of the expanded CD25 + bulk cells because they efficiently inhibited the proliferation of autologous CD4 + and CD8 + peripheral blood-derived responder cells in a dose-dependent fashion (Fig. 3A-B) .
Of note, UC-specific immunosuppression can only be induced with knowledge of the antigens which are targeted by the ongoing immune response. Because the antigens directing gutspecific inflammation are largely unknown, the application of polyclonal Treg is likely more efficient than that of monoclonal Treg. We, therefore, evaluated the TCR repertoire on the expanded CD4 + CD25 + cells by staining them with a panel of 24 distinct TCR Vb monoclonal antibodies, which cover approximately 70% of the human TCR Vb repertoire. As shown in Figure 3C , expanded CD4 + CD25 + cells expressed all 24 TCRs, indicating that the expanded cells are polyclonal and, as such, able to recognize a wide variety of antigens.
Expanded CD25 + Cells Express a4b7 and Are Able to Suppress Colon-derived CD8 + T Cells
Expression of receptors associated with gut-homing and the potential to inhibit colon-derived T cells are likely to play an important role in the ability of the expanded Treg to ameliorate UC in patients. We therefore assessed the expression of the guthoming receptor a4b7 by flow cytometry in expanded Treg from 2 patients with UC. In agreement with previously published data, 37 expanded Treg from both patients expressed 59.9% and 54.1% a4b7 (Fig. 4A) .
We next assessed whether expanded Treg were able to inhibit proliferation of colon-derived responder cells. For this purpose, colon biopsies from 12 patients suffering from inflammatory bowel disease (IBD), including 4 patients with UC and 8 patients with Crohn's disease (CD), were processed into single cell suspensions and cocultured with expanded Treg. Expanded Treg significantly inhibited proliferation of CD8 + colon-derived responder cells (Fig. 4B, C) in a dose-dependent fashion (2:1 versus 1:1 P ¼ 0.0207; 2:1 versus 1:2 P ¼ 0.0001), whereas expanded Treg failed to inhibit proliferation of CD4 + colonderived responder cells (2:1 versus 1:1 P ¼ 0.3716; 2:1 versus 1:2 P ¼ 0.2419) (Fig. 4B, D) .
Ex Vivo Expansion Simultaneously Induces CD8 + Treg Cells
With respect to immunological self-tolerance and autoimmunity, CD4 + CD25 + cells have widely been studied. However, the role of CD8 + CD25 + cells in the regulation of tolerance is also increasingly considered. 38, 39 Because of our IRB limitation, we were only able to expand CD25 + bulk cells consisting of both CD4 + and CD8 + cell subsets. As shown in Figure 5A , B, flow cytometry staining revealed that a subset of the CD8 + CD25 + cells also expressed FoxP3, although the majority of cells in the expanded CD25 + bulk cell products represented CD4 + FoxP3 + T cells.
Specifically, 20.9% CD8+FoxP3+ cells (range 9.1%-35.4%, n ¼ 4) were present in the CD25 + cell population after CD25 + enrichment at day 0. During the expansion process, their number gradually increased to 55.1% CD8+FoxP3 cells at day 21 (range 22.6%-72.0%, n ¼ 4), but this increase did not reach significance (P ¼ 0.1388). The final CD4+:CD8+ Treg ratio in the expanded cell population was 65:1 (range 2:1-491:1, n ¼ 9).
To evaluate the potential of expanded CD8 + CD25 + cells to also suppress proliferation of autologous peripheral blood-derived responder cells, the 2 cell subsets were separated by FACS sorting (Fig. 6A) and their ability to inhibit autologous responder cell proliferation was measured by CFSE dilution. Both expanded CD4 + CD25 + (Fig. 6B-C) and CD8 + CD25 + (Fig. 6D-E ) cells suppressed autologous peripheral blood-derived CD4 + and CD8 + T cells in a dose-dependent fashion.
As a first step in characterizing the CD8 + Treg cells, we compared the methylation status of CD25 + bulk cells with their FACS-sorted CD4 + and CD8 + counterparts. As expected, day 0 CD25 + bulk cells, day 21 CD25 + bulk cells, and day 21 FACS-sorted CD4 + CD25 + cells were mainly hypomethylated at intron 1 of the FoxP3 locus. By contrast, day 21 CD8 + CD25 + cells were mainly methylated at intron 1 of the FoxP3 locus (Fig. 6F) .
Overall, these data demonstrate that both CD4 + and CD8 + Treg can be expanded from CD25 + bulk cells derived from patients with UC.
CD25 + Cell-mediated Suppression Relies on the Secretion of Soluble Factors and Is Associated with a Decrease in CD8 + T Effector Cells
As a first step to unravel the mechanism responsible for Treg-mediated suppression in UC, an additional set of CFSE dilution assays was performed with day 21-expanded CD25 + bulk cells. Through the addition of an insert, direct Treg to responder cell interactions were prevented. As demonstrated in Figure 7A -B, the physical separation of expanded CD25 + cells from autologous CD25 2 cells did not affect CD25 + cell-mediated cell suppression because the proliferation of autologous CD8 + effector T cells was equally inhibited in a dose-dependent fashion (P ¼ 0.1322 at 1:1; P ¼ 0.3377 at 1:5; and P ¼ 0.4279 at 1:10). To begin to understand which factors could be responsible for Treg-mediated effector T-cell inhibition, we sought to associate Treg-mediated inhibition with cellular degranulation, as characterized by surface expression of the degranulation marker CD107a. Treg-mediated inhibition was associated with upregulation of CD107a (mean 83.7%, range 52.2%-99.6%; n ¼ 3), as indicated in Figure 7C . Furthermore, the percentage of CD8 + effector T cells decreased during the CFSE dilution assay in a dose-dependent fashion (Fig. 7D-E) . These data suggest that expanded CD25 + cells derived from patients with UC secrete soluble factors, including toxic granules, which are also able to directly eliminate autologous CD8 + responder cells.
DISCUSSION
Previous studies on Treg-based therapy for inflammatory bowel diseases mainly considered the possibility to treat patients with Crohn's disease. 11, 40 In this study, we developed a GMPconform protocol for patients with UC that provides a rational backbone for the design of a clinical phase 1 study on Treg therapy in this disease. Importantly, the presented expansion protocol has received GMP certification from the Bavarian government. Minor modifications were necessary for clinical translation of the presented protocol. First, autologous serum was replaced by autologous plasma, since from a clinical perspective, it is not possible to obtain enough patient serum to cover the whole expansion process. Second, to avoid the transfer of simultaneously expanded CD8 + CD25 + and CD19 + CD25 + cells, a CD8 + and CD19 + cell depletion step was added at day 14 of the GMPapproved expansion protocol.
For the Treg-production process to be successful, ex vivo Treg expansion should be robust and not be influenced by disease severity or ongoing systemic treatment, since most patients will take immunosuppressive drugs at the time of leukapheresis, subsequent Treg isolation and expansion. The fact that functional Treg cells could be isolated and ex vivo expanded, despite ongoing therapy with for example the anti-tumor necrosis factor antibody infliximab, is essential for successful clinical translation of the presented findings.
Two prerequisites for the treatment of UC with adoptively transferred Treg are (1) their potential to home into the inflamed gut and (2) to induce suppression on encounter with autologous effector T cells. UC-derived Treg cells, which are expanded with the presented protocol, are likely to fulfill these 2 criteria. Specifically, it is now clear that, at least in part, effector T cell-specific gut homing is mediated by the specific interaction between a4b7 and its ligand MAdCAM-1. 41, 42 We here show that rapamycin-expanded UC-derived Treg cells maintain a4b7 expression after 21 days of ex vivo expansion. In addition, because little is known about the antigens directing gut-specific inflammation, the application of polyclonal Treg is likely to be more efficient than that of monoclonal antigen-specific Treg. We demonstrate by TCR Vb analysis that UC patient-derived expanded Treg are polyclonal, which predicts a broad autoantigen repertoire. This finding is also relevant regarding gut-specific homing because polyclonality has been shown to be a requirement for Treg to maintain intestinal homeostasis. 43 Moreover, expanded Treg inhibited the proliferation of colon-derived CD8 + T cells in a dose-dependent fashion. This is an important finding because emerging data suggest that select signals, including Smad7, 35 induce resistance of local colonic T cells to Tregmediated suppression. The reason for the inability to also suppress colon-derived CD4 + T cells is currently unclear. One explanation could be the use of allogeneic colon-derived CD8 + T cells and not autologous colon-derived CD8 + T cells. Alternatively, because of the limited number of cells in the cell suspensions derived from the colon biopsies, Treg coculture assays were performed with all cells present in the cell suspension, including epithelial cells. Therefore, direct negative effects on Treg-mediated T-cell suppression cannot be excluded. Additional experiments are planned, as part of the proposed phase I clinical trial, to study Treg-mediated suppression of autologous colon-derived T cells. Interestingly, emerging evidence shows that several subsets of CD8 suppressor cells exist, 38, 39 although their mode of action remains undefined. [44] [45] [46] Consistent with the idea that rapamycin imprints a fixed phenotype to the expanded CD4 + CD25 + cells, we found that CD8 + CD25 + cells also inhibited proliferation of autologous CD8 + and CD4 + effector T cells. However, in contrast to expanded CD4 + CD25 + cells, expanded CD8 + CD25 + cells showed an epigenetically unstable FOXP3 locus because they were mainly hypermethylated at intron 1. This suggests that most CD8 + Treg are actually induced in the presence of rapamycin, IL-2, and anti-CD3/anti-CD28 expander beads. This finding has potential clinical implications because CD8 + Treg have already been shown to prevent experimental colitis in mice. 45 Therefore, their inclusion in future adoptive Treg transfer protocols should be considered.
Finally, one major concern regarding the use of autologous ex vivo-expanded Treg in Treg-based clinical studies is the risk of their in vivo conversion into effector T cells and loss of suppressive ability. The group of Tresoldi et al studied the potential of Treg expanded in the presence of rapamycin to convert into IL-17-producing effector (Th17) T cells. They found both in vitro and in vivo in NOD/SCID mice that rapamycin allows the ex vivo expansion of Treg voided of effector T cells. In addition, Treg retained suppressive capacity up to 19 days after adoptive transfer. 26 Under our expansion conditions, Treg derived from patients with UC were confirmed to not secrete high levels of IL-2, INF-g, and IL-17 on TCR stimulation and maintained Treg-specific demethylated region status after ex vivo expansion. In addition, UC-expanded Treg did not secrete IL-10, yet expressed transforming growth factorb-associated LAP, which further confirms their true Treg origin. 47 In addition, several studies suggest that Crohn's disease is driven by exaggerated Th1 and Th17 responses, whereas UC is associated with a Th2 profile. [48] [49] [50] To further circumvent the potential of Th17 differentiation of infused Treg, we elected to choose UC as the disease to assess safety and tolerability of our autologous ex vivo-expanded Treg in a first-in-man clinical trial. In summary, our findings reveal that UC patient-derived expanded CD25 + cells are stable and functional. Although our experiments do not specifically address the efficacy of the expanded Treg to ameliorate gut-specific inflammation in UC, they support future phase I dose-escalation safety studies.
